# Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

> **NCT05599984** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 288 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ABBV-706
- **DRUG:** Cisplatin
- **DRUG:** Budigalimab
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05599984
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-05
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 288 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05599984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05599984, "Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT05599984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*